Netherlands-based pharma group Norgine has expanded its rare disease portfolio with the acquisition of France's Theravia for an undisclosed sum.

L’exceptionnel site logistique d’Amazon, dont les travaux sont lancés à Illiers-Combray, fait partie des dossiers dévoilés par Emmanuel Macron, à Versailles, lors du sommet Choose France, ce lundi 19 ...

Norgine proudly announces the TGA registration of PEDMARQSI®, which protects children from cisplatin-induced hearing loss during chemotherapy.

Norgine has announced the TGA's approval of PEDMARQSI® in Australia, a groundbreaking treatment for preventing cisplatin-induced hearing loss in children undergoing chemotherapy.

Norgine has received EU marketing authorisation for XOLREMDI® (mavorixafor), the first treatment for WHIM syndrome, enhancing care for affected individuals.

Norgine announces the TGA registration of PEDMARQSI®, a new treatment to prevent hearing loss caused by cisplatin in children, providing hope for many families.

Norgine proudly announces the TGA registration of PEDMARQSI®, a breakthrough treatment designed to prevent cisplatin-induced hearing loss in children, marking a significant advance in pediatric oncology care.

Norgine announces the TGA registration of PEDMARQSI® in Australia for preventing cisplatin-induced hearing loss in children aged under 18. This marks a significant step in pediatric oncology care.

Norgine's acquisition of Theravia enhances its rare disease pharmaceutical offerings, broadening access to innovative treatments across Europe.

Norgine's marketing authorisation of XOLREMDI® marks a significant advancement in treating WHIM syndrome, benefiting patients across the EU.

Norgine's recent EU marketing authorization for XOLREMDI® marks a significant step for WHIM syndrome patients, opening new treatment options.

Norgine has made a significant move by acquiring Theravia, expanding its rare disease portfolio. This acquisition positions Norgine as a leading partner in the specialty pharma market.

X4 Pharmaceuticals (Nasdaq:XFOR) reported financial results for the quarter ended June 30, 2026 and detailed progress across its rare hematology portfolio. Revenue was $8.8 million for the quarter and $11.5 million for the first half of 2026, including $2.4 million and $4.8 million in net U.S. XOLREMDI® product sales and $6.4 million and $6.7 million in license and other revenue, largely from its Norgine agreement.Research and development expenses declined to $15.1 million in the quarter, while general and administrative expenses fell to $8.5 million. Net loss narrowed to $16.2 million, or $(0.13) per share, for the quarter. Cash, cash equivalents, and marketable securities totaled approximately $208 million at June 30, 2026, which the company said provides a cash runway into 2029. Operationally, X4 transitioned management of its global Phase 3 4WARD chronic neutropenia trial to a premier CRO, continued enrolling patients at over 110 sites, and expects an FDA meeting update and enrollment completion timing by the end of the third quarter of 2026. The European Commission granted marketing authorization for XOLREMDI for WHIM syndrome, with commercialization in Europe led by partner Norgine and up to an additional €221 million in potential milestones plus escalating double-digit royalties.